Silver Book Fact

AFib practice guidelines reduce direct health care costs

The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.

Zimetbaum P, Reynolds M, Ho K, Gaziano T, et al. Impact of a Practice Guideline for Patients with Atrial Fibrillation on Medical Resource Utilization and Costs. Am J Cardiol. 2003; 92(6): 677-81. http://www.ajconline.org/article/S0002-9149(03)00821-X/abstract

Reference

Title
Impact of a Practice Guideline for Patients with Atrial Fibrillation on Medical Resource Utilization and Costs
Publication
Am J Cardiol
Publication Date
2003
Authors
Zimetbaum P, Reynolds M, Ho K, Gaziano T, et al
Volume & Issue
Volume 92, Issue 6
Pages
677-81
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.